- Home
- IMCR vs EVT Comparison
IMCR vs EVT Comparison
Compare IMCR & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- EVT
- Stock Information
- Founded
- IMCR 2008
- EVT 2003
- Country
- IMCR United Kingdom
- EVT United States
- Employees
- IMCR N/A
- EVT N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- EVT Finance Companies
- Sector
- IMCR Health Care
- EVT Finance
- Exchange
- IMCR Nasdaq
- EVT Nasdaq
- Market Cap
- IMCR 1.7B
- EVT 1.9B
- IPO Year
- IMCR 2021
- EVT N/A
- Fundamental
- Price
- IMCR $34.26
- EVT $24.54
- Analyst Decision
- IMCR Buy
- EVT
- Analyst Count
- IMCR 9
- EVT 0
- Target Price
- IMCR $57.00
- EVT N/A
- AVG Volume (30 Days)
- IMCR 287.1K
- EVT 115.5K
- Earning Date
- IMCR 11-05-2025
- EVT 01-01-0001
- Dividend Yield
- IMCR N/A
- EVT 8.32%
- EPS Growth
- IMCR N/A
- EVT N/A
- EPS
- IMCR N/A
- EVT 6.63
- Revenue
- IMCR $356,145,000.00
- EVT $69,404,302.00
- Revenue This Year
- IMCR $29.71
- EVT N/A
- Revenue Next Year
- IMCR $11.27
- EVT N/A
- P/E Ratio
- IMCR N/A
- EVT $3.55
- Revenue Growth
- IMCR 26.78
- EVT N/A
- 52 Week Low
- IMCR $23.15
- EVT $19.20
- 52 Week High
- IMCR $39.33
- EVT $25.83
- Technical
- Relative Strength Index (RSI)
- IMCR 49.34
- EVT 60.30
- Support Level
- IMCR $33.92
- EVT $24.41
- Resistance Level
- IMCR $37.00
- EVT $24.52
- Average True Range (ATR)
- IMCR 1.45
- EVT 0.26
- MACD
- IMCR -0.06
- EVT 0.03
- Stochastic Oscillator
- IMCR 39.78
- EVT 72.65
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.